trending Market Intelligence /marketintelligence/en/news-insights/trending/t0fsd69hdqx8j_-knqh6a2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Gates Foundation to advance HIV prevention with $140M investment

Municipal CUSIP Requests Knocked Off of Record Pace by November Decrease

Street Talk Episode 53 - Nancy Bush Questions Large Bank MOEs, Future Of Independent Research

US Broadband Only Homes Surge In Q3 Ahead Of Disney+ Launch

Architectural Shift In 5G Core Needed To Meet IoT Demands

Gates Foundation to advance HIV prevention with $140M investment

The Bill & Melinda Gates Foundation is investing up to $140 million in Intarcia Therapeutics Inc. as part of an effort to combat HIV.

Intarcia Therapeutics is developing an anti-HIV vaccine that would be administered annually or semi-annually in sub-Saharan Africa and other countries where the epidemic is most severe.

The company attracted funding from the Gates Foundation during its second series EE equity financing which yielded $206 million in proceeds.

The Gates Foundation committed $50 million during the financing and has agreed to pay up to a further $90 million in milestone-related payments to the HIV vaccination.